doi: 10.1161/CIRCULATIONAHA.106.624296
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1109-1123.)
© 2007 American Heart Association, Inc.
Heart Disease in Latin America |
Pathogenesis of Chronic Chagas Heart Disease
From the Cardiology Division (J.A.M.-N., B.C.M., M.V.S.), Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo; the Heart Institute (InCor), University of São Paulo, and Institute for Investigation in Immunology, Millenium Institutes–Conselho Nacional de Pesquisa (E.C.-N.), São Paulo, Brazil.
Correspondence to Jose A. Marin-Neto, MD, PhD, AV Bandeirantes, 3900 Ribeirão Preto, São Paulo, Brazil 14048-900. E-mail marin_neto{at}yahoo.com
Received March 3, 2006; accepted May 26, 2006.
 |
Abstract |
|---|
 Top Abstract IntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Background— Chagas disease remains a significant public health issue and a major cause of morbidity and mortality in Latin America. Despite nearly 1 century of research, the pathogenesis of chronic Chagas cardiomyopathy is incompletely understood, the most intriguing challenge of which is the complex host-parasite interaction.
Methods and Results— A systematic review of the literature found in MEDLINE, EMBASE, BIREME, LILACS, and SCIELO was performed to search for relevant references on pathogenesis and pathophysiology of Chagas disease. Evidence from studies in animal models and in anima nobile points to 4 main pathogenetic mechanisms to explain the development of chronic Chagas heart disease: autonomic nervous system derangements, microvascular disturbances, parasite-dependent myocardial aggression, and immune-mediated myocardial injury. Despite its prominent peculiarities, the role of autonomic derangements and microcirculatory disturbances is probably ancillary among causes of chronic myocardial damage. The pathogenesis of chronic Chagas heart disease is dependent on a low-grade but incessant systemic infection with documented immune-adverse reaction. Parasite persistence and immunological mechanisms are inextricably related in the myocardial aggression in the chronic phase of Chagas heart disease.
Conclusions— Most clinical studies have been performed in very small number of patients. Future research should explore the clinical potential implications and therapeutic opportunities of these 2 fundamental underlying pathogenetic mechanisms.
Key Words: autonomic nervous system • cardiomyopathy • Chagas disease • immune system • inflammation • microcirculation • Valsalva maneuver
|
Introduction |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
A unique accomplishment in the history of medicine was the discovery by the Brazilian physician Carlos Chagas at the beginning of the 20th century of a new morbid entity—one that is by no means uncommon; rather it afflicts millions of patients.1 Besides describing most clinical features of the disease, Chagas also characterized its causal agent, the Trypanosoma cruzi, and the main mechanism of disease transmission, transcutaneous inoculation of the parasite by infected excreta of hematophagous insects.
Although chagasic megaesophagus and megacolon produce typical clinical conditions in 5% to 10% of patients, Chagas cardiomyopathy is by far the most serious form of the disease.2 Despite nearly a century of research, the most intriguing challenge to understanding the pathophysiology of Chagas heart disease still lies in the complex host-parasite interrelationship.3 This interaction, through mechanisms that are still not fully understood, determines that the myocardial aggression remains controlled at low levels in many patients. These patients remain throughout life with the so-called indeterminate form.4 Conversely, in 30% to 40% of patients the development of full-blown chronic Chagas cardiomyopathy is triggered, which leads to sudden death, complex arrhythmias, ventricular aneurysms (Figures 1 and 2
), heart failure, and thromboembolism.5
|
|
From the evidence gathered through studies in animal models and in humans, 4 main pathogenetic mechanisms have been advocated to explain the development of Chagas heart disease: cardiac dysautonomia, microvascular disturbances, parasite-dependent myocardial damage, and immune-mediated myocardial injury.
|
Dysautonomia |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Evidence of autonomic derangements in Chagas disease can be traced back to the primordial studies of Carlos Chagas and the cardiologist Eurico Vilella, when they reported in 1922 blunted chronotropic responses to atropine in chagasic patients.6 Over the following 2 decades, however, the disease fell into virtual neglect by the medical community. Only in the late 1940s, through improved specific serological tests to detect antibodies against T cruzi, the clinical syndromes of megaesophagus, megacolon, and heart failure, by then of unknown cause, were ascribed to Chagas disease, and the first report of cardiac neuronal damage appeared in the literature.7
Pathological Evidence of Cardiac Denervation
Possibly aware of Carlos Chagas’s early studies, some of which were published in German, Fritz Köberle, an Austrian pathologist who moved to Ribeirão Preto, Brazil, in the 1950s, conducted systematic studies of the intrinsic nervous system in organs that exhibited the pathological alterations caused by Chagas disease. He standardized the technique of cardiac intramural neuronal counting in microscopic sections obtained from the intercaval atrial strip and described intense neuronal depopulation in chagasic patients.8,9 The ganglionic damage and absolute reduction in subepicardial intramural neuronal countings (Figure 3) were confirmed by other independent investigators who used the Köberle method and other less systematic approaches in autopsied patients.10,11 These findings have been corroborated by studies in animals experimentally infected with the T cruzi, which demonstrated cardiac neuronal parasitism associated with periganglionitis and degenerative abnormalities in Schwann cells and nervous fibers.12,13
|
Subsequent studies showed that parasympathetic neuronal depopulation is not specific for Chagas disease. However, in all autopsy direct comparisons of subepicardial atrial denervation in inflammatory (rheumatic) and noninflammatory heart disease (endomyocardial fibrosis, dilated cardiomyopathy), the absolute reduction in the parasympathetic neuronal countings was more conspicuous in chagasic patients.14–16 The neuronal loss in Chagas heart disease has been postulated to occur predominantly during the acute phase of the infection, with participation of 3 mechanisms: direct parasitism of neurons, degeneration caused by periganglionic inflammation, and antineuronal autoimmune reaction.17,18
Functional Evidence of Cardiac Denervation
Consistent with anatomic parasympathetic denervation shown by morphological studies, abnormal cardiac autonomic regulation has been conclusively demonstrated in chagasic patients. Various pharmacological and physiological stimuli were used to demonstrate impaired parasympathetic heart rate regulation: metaraminol, phenylephrine and atropine intravenous injections, facial immersion, Valsalva maneuver, head-up and head-down tilt tests, respiratory sinus arrhythmia, hand grip, graded dynamic exercise, and spectral analysis of Holter recordings.19–27 Overall, these studies showed that chagasic patients are usually deprived of the tonic inhibitory action normally exerted by the parasympathetic system on the sinus node, and chagasic patients lack the vagally mediated mechanism to respond with rapid bradycardia or tachycardia to transient changes in blood pressure or venous return28,29 (Figure 4).
|
The autonomic dysfunction in chagasic patients can be detected before the development of ventricular dysfunction and in all phases of the disease, even the indeterminate and digestive forms.25,30,31 Thus, it is distinct from the nonspecific autonomic impairment that occurs in heart failure of whatever etiology, which is related to neurohumoral activation and postsynaptic desensitization of ß-adrenergic receptor pathways32,33 and can be at least partially reversible with clinical control.34
Neurogenic Hypothesis of Chagas Cardiomyopathy
So striking was the intramural neuronal depopulation in some chagasic patients that Köberle postulated it should constitute the main mechanism of cardiomegaly and enteromegaly in Chagas disease. In fact, neuronal depopulation invariably occurs in patients with megaesophagus and megacolon35,36 and the aperistalsis thus caused is generally considered the essential pathogenetic mechanism of chagasic digestive organic involvement.37 Because the intramural cardiac ganglia are mostly parasympathetic, the Köberle neurogenic theory of Chagas disease pathogenesis proposed that, similar to digestive organic involvement, Chagas cardiomyopathy was "parasympathicopriva": in essence, it postulated that a long-lasting autonomic imbalance would eventually lead to a catecholamine-induced cardiomyopathy.8,38 However, pathogenesis of Chagas heart disease is definitely more complex, and the neurogenic theory for Chagas cardiomyopathy met several unsolvable conceptual obstacles, which are detailed in Table 1.
|
Detection of cardiac dysautonomia in all those studies was based solely on heart rate assessment and was caused by damage in the neuronal supply to the sinoatrial structures. Hence, nerve damage that occurred at the ventricular myocardial level may have been overlooked. A more detailed study focused on iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy for evaluation of myocardial sympathetic nerve inervation45; segmental sympathetic denervation was detected even in patients with the indeterminate form of Chagas heart disease before left ventricular (LV) wall motion abnormalities. An additional intriguing finding from that study was the increased 123I-MIBG washout rate observed in patients with normal ventricular function.46 This could be the result of increased cardiac sympathetic activity at the early stage of Chagas disease, which thus lends support to the neurogenic theory stated above. This abnormality could instead be caused by competition between the radiotracer and endogenous substances for the neurotransmitter receptors at the sympathetic nerve terminals, however. In fact, recent reports documented the existence of circulating antibodies that bind to myocardial adrenergic and cholinergic receptors in patients with Chagas disease.47,48 These antibodies have been shown to trigger physiological, morphological, enzymatic, and molecular alterations, and could potentially cause myocardial damage, desensitization, or downregulation of both muscarinic and adrenergic receptors.
Pathophysiological Impact of Sinoatrial Denervation
It is unlikely that autonomic dysfunction plays an essential pathogenic role for the development of chronic Chagas cardiomyopathy. Conversely, it is naïve to conclude that such a striking disturbance in many chagasic patients would have no deleterious consequences. It is conceivable that neurogenic disturbances may be a contributory factor to the complications of the chronic phase of Chagas disease in at least 3 pathophysiological ways:
- A. Early parasympathetic impairment could be a mechanism that triggers sudden death.49 This possibility is indirectly supported by autopsy reports of small, highly denervated hearts in patients who died suddenly16; although the parasympathetically denervated chagasic heart could indeed be more vulnerable to malignant arrhythmia that is potentially able to trigger sudden death, this hypothesis has never been tested in appropriately designed clinical studies.
- B. Dyssynergic areas develop in both ventricles at early stages of Chagas cardiomyopathy. Although the autonomic impairment is not causally responsible for the contraction abnormalities, it may aggravate these disturbances and lead to depression of global ventricular function in a subtle way: The parasympathetically denervated chagasic heart is deprived of the physiological mechanism of homeometric self-regulation warranted by fast heart-rate responses to a variety of physiological stimuli. Without the vagal mechanism to respond with rapid chronotropic changes, the chagasic heart depends more on heterometric adjustments that require more conspicuous variations in ventricular volume and shape during transient increases of venous return and ventricular afterload. In support of this hypothesis, it has been shown that chagasic patients respond to blood flow demand imposed by physical exercise with a greater increase in stroke volume23; this compensates for deficient chronotropic changes during exercise, but clearly occurs at the expense of a reserve mechanism that requires ventricular dilatation, more forceful contraction, or both. Also in contrast to normal individuals, chagasic patients that show deficient chronotropic parasympathetic control have more marked elevation of peripheral resistance in response to the orthostatic stress29 and less increase in cardiac output during isometric exercise.50 These hemodynamic studies illustrate how denervated chagasic patients constantly face more stressful adaptation to intrinsically physiological conditions, which potentially lead to increased afterload and chamber dilatation.
- C. Autonomic derangements may be responsible to trigger microcirculatory vasospasm, as discussed below.
- B. Dyssynergic areas develop in both ventricles at early stages of Chagas cardiomyopathy. Although the autonomic impairment is not causally responsible for the contraction abnormalities, it may aggravate these disturbances and lead to depression of global ventricular function in a subtle way: The parasympathetically denervated chagasic heart is deprived of the physiological mechanism of homeometric self-regulation warranted by fast heart-rate responses to a variety of physiological stimuli. Without the vagal mechanism to respond with rapid chronotropic changes, the chagasic heart depends more on heterometric adjustments that require more conspicuous variations in ventricular volume and shape during transient increases of venous return and ventricular afterload. In support of this hypothesis, it has been shown that chagasic patients respond to blood flow demand imposed by physical exercise with a greater increase in stroke volume23; this compensates for deficient chronotropic changes during exercise, but clearly occurs at the expense of a reserve mechanism that requires ventricular dilatation, more forceful contraction, or both. Also in contrast to normal individuals, chagasic patients that show deficient chronotropic parasympathetic control have more marked elevation of peripheral resistance in response to the orthostatic stress29 and less increase in cardiac output during isometric exercise.50 These hemodynamic studies illustrate how denervated chagasic patients constantly face more stressful adaptation to intrinsically physiological conditions, which potentially lead to increased afterload and chamber dilatation.
It is noteworthy that circulatory dysautonomia in Chagas disease differs from other syndromes that affect the autonomic nervous system (eg, diabetes mellitus, amyloidosis), because no significant adrenergic vascular abnormality that leads to symptoms or objective evidence of postural hypotension exists. Moreover, there has been no demonstration that autonomic impairment per se is prognostically relevant, and no therapeutic implications are devised. Finally, in many studies the cardiac autonomic impairment was very subtle, and minuscule differences in comparison to normal controls may have been over interpreted.
|
Microvascular Disturbances |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Various lines of evidence from pathological, experimental, and clinical grounds suggest that microvascular abnormalities that lead to myocardial ischemia may contribute to the pathogenesis of Chagas heart disease.
Histopathology Studies in Humans
The first reports on the pathology of the acute phase of Chagas heart disease implicated vascular disturbances caused by perivascular inflammation as mechanisms for myocardial degeneration.51 The concept was revived in necroscopic studies of chronic patients, which described diffuse collapse of intramyocardial arterioles, with lumen constriction attributed to intimal proliferation.52 These microvascular abnormalities were deemed responsible for the focal diffuse myocytolysis observed in these necroscopic studies and also in biopsy specimens that showed extensive capillary basement membrane thickening.53 Several subsequent investigations reinforced the notion of abnormal vasodilatation and vasoconstriction at the microcirculatory level that cause myocardial damage in patients with Chagas disease.5,9,54,55 Also, on the basis of the focal distribution of cell necrosis and subsequent reparative interstitial fibrosis found in chagasic hearts, which was similar to what is seen in experimental models of ischemia and reperfusion, transient microvascular ischemic disturbances of low intensity and short duration have been postulated to be causative mechanisms of Chagas cardiomyopathy.56,57 Among factors that lead to the development of aneurysms in chagasic patients, coalescent microinfarctions have been postulated to occur in watershed coronary areas because of unopposed sympathetic overstimulation.58 This last notion has been considered a pathophysiological link between the microcirculatory hypothesis and the neurogenic theory of Chagas heart disease.
Experimental and In Vitro Studies
In experimental murine models of Chagas disease, microcirculatory derangements include the occurrence of occlusive platelet thrombi in small epicardial and intramural coronary arteries, which lead to ischemia detected in vivo by histochemical techniques.59,60 Focal vascular constriction and microvascular proliferation were also prominent structural abnormalities in this experimental model.61 To elucidate the mechanisms responsible for the occlusive platelet thrombosis and microcirculatory spasm, a direct participation of T cruzi infection that causes endothelial cell damage62 and endothelium damage by immune effector cells63 have been reported. Also, in vitro T cruzi infection of human umbilical vein demonstrated increased production of endothelin, which mediates arteriolar spasm and inhibits cAMP, with consequent stimulation of platelet adhesion to the vascular wall.64 Trypomastigote forms of T cruzi also produce a neuraminidase that removes the sialic acid from the surface of mammalian myocardial and endothelial cells.65 The loss of this protective component of the endothelial surface may cause platelet aggregation and microvascular thrombosis. These abnormal findings are corroborated by the demonstration of increased levels of thromboxane-A2 and enhanced platelet adherence and aggregation in T cruzi–infected mice.66 Local production of cytokines by the inflammatory infiltrate cells may also contribute to microvascular abnormal reactivity in the chagasic heart. This has been shown to be partially reversible by long-term administration of verapamil, a calcium channel blocker with vasodilating and anti-platelet–aggregating effects that lead to attenuation of myocardial lesions and increased survival in a murine model of Chagas disease.67 This hypothesis was further supported by a study that used in vivo visualization of the murine cremaster vascular bed. In comparison with control animals, animals infected with T cruzi had segmental arteriolar spasm and flow velocity reduction; these abnormalities were also reversed by verapamil.68 Finally, recent data showed that calreticulin, a calcium-binding protein present in T cruzi that is quite similar to its human counterpart, may modulate the complement system and inhibit angiogenesis. This could constitute a potential molecular mechanism that leads to microvascular damage and dysfunction.69
Clinical Studies
Various clinical aspects of Chagas heart disease suggest the participation of myocardial ischemia in its pathophysiology. A substantial proportion of chagasic patients (20% to 30%) complain of chest pain that resembles angina in location and character, but this pain has no consistent relationship to effort and is not relieved by nitrates. Many patients have concomitant ST-T changes and abnormal Q waves compatible with electrically inactive ventricular areas.5,70,71 Furthermore, similar to coronary artery disease, segmental LV dysfunction is common in chagasic patients, even those with dilated hearts.72 Despite these findings that suggest the occurrence of myocardial ischemia, coronary angiography in Chagas cardiomyopathy invariably demonstrated the absence of obstructive disease at the epicardial level.70,73,74 Nevertheless, consistent with the experimental studies, impairment of endothelium-dependent coronary vasodilatation in response to acetylcholine, with preserved response to adenosine, has been reported in patients with Chagas heart disease.75 Also, chagasic patients with atypical angina that was severe enough to warrant coronary angiography were shown to have blunted vasomotor epicardial responses to hyperventilation and dinitrate isosorbide.76 Taken together, these findings show abnormal coronary flow regulation related to endothelial and nonendothelium dysfunction in chagasic patients with chest pain and angiographically normal epicardial coronary arteries.
Several independent investigations have shown striking myocardial perfusion abnormalities in chagasic patients with angiographically normal coronary arteries, and these studies lend support to the concept of abnormal myocardial flow regulation at the microvascular level74,77,78 (Figure 5). In one of these investigations that used 201thallium stress-redistribution myocardial perfusion scintigraphy, every type of perfusion defect was seen in all 23 chagasic patients studied; although fixed defects that denoted myocardial fibrosis were found in myocardial segments that exhibited akinesis or dyskinesis, stress-induced reversible myocardial ischemia was detected in LV segments with less severe wall motion impairment in 8 patients (35%).78 Another study that used 201thallium single photon emission computed tomography myocardial scintigraphy focused on the topographical correlation between segmental myocardial perfusion abnormalities and regional LV dysfunction in 37 patients with various stages of Chagas heart disease; again, some kind of perfusion defects (fixed, paradoxical, and reversible) were seen in 78% of patients. Significant topographical correlation occurred between perfusion changes and wall motion abnormalities that predominated in the apical and inferior-posterior LV segments. Reversible stress-induced myocardial perfusion defects were detected in segments that exhibited normal wall motion in 5 of 12 chagasic patients with no other evidence of myocardial disease. Of note, these reversible ischemic defects were seen in the apical and inferior-posterior LV segments (ie, the same regions where regional contractile dysfunction prevails in later stages of Chagas cardiomyopathy).45
|
The tracer used in the studies quoted above was 201thallium, whose accumulation and retention could be influenced by cardiomyocyte metabolic derangements related to the underlying inflammatory process. Hence, some of the scintigraphic defects described in the previous studies could be independent of real perfusion abnormalities. This alternative possibility is reinforced by the frequent occurrence in those studies of reverse redistribution defects that predominate in LV regions with normal or mildly impaired wall motion. However, myocardial perfusion was also evaluated in 18 chronic Chagas heart disease patients with recurrent chest pain severe enough to warrant coronary angiography with an exclusive perfusion tracer, 99mtechnetium-labeled microspheres injected in the LV cavity.76 None of the patients had angiographic evidence of apical coronary artery disease. Ten of the 18 patients exhibited extensive perfusion defects in 49 of 126 (39%) LV segments. Nineteen of these segments (40%) with perfusion defects had severely impaired wall motion, which probably corresponded to extensive fibrosis. The remaining 60% of the segments with perfusion defects had normal or mildly reduced wall motion. Thus, this investigation clearly showed marked resting myocardial perfusion abnormalities before the appearance of wall motion impairment.
Pathophysiological Consequences of Microvascular Derangements
On the basis of these clinical investigations and the background information provided by the experimental studies discussed above, it is a reasonable hypothesis that chronic myocardial hypoperfusion would contribute as a pathogenetic mechanism to the development of the characteristic regional LV dysfunction seen in Chagas heart disease. This would be similar to hibernating myocardium seen in chronic coronary artery disease, and this might have relevant clinical implications for the management of chagasic patients. This hypothesis is compatible with the results of studies that show improvement of LV function in Chagas heart disease patients who received short-term or long-term administration of dipyridamole79 and isosorbide dinitrate.80 In these studies, however, no clear relationship between the LV function improvement and the relief of myocardial ischemia was demonstrated. Moreover, changes in ventricular loading conditions associated with these modalities of treatment could also have contributed to the improvement in the ventricular performance. Thus, although attractive, the hypothesis of chronic myocardial ischemia in Chagas cardiomyopathy still awaits the conclusive support that should be derived from a prospective cohort study that shows a beneficial effect of long-term vasodilator or antiplatelet therapy on the clinical course of chagasic patients with angina-like symptoms.
It should be emphasized that the triad of chest pain, myocardial perfusion disturbances, and normal coronary arteries has also been described in patients with ventricular dysfunction caused by dilated cardiomyopathy of other causes.81 Therefore, this is not a specific feature of Chagas cardiomyopathy. Moreover, no prospective cohort studies have been conducted that correlate the presence and extent of myocardial perfusion disturbances with the temporal development of segmental LV wall motion abnormalities in the same chagasic patients.
In summary, despite these limitations, experimental and clinical studies strongly support the notion that functional and structural microvascular abnormalities occur in Chagas cardiomyopathy, possibly as a consequence of the underlying inflammatory process. Thus, it is possible that microvascular ischemia, even if it is not an independent and self-sustained pathogenetic mechanism, could at least constitute an ancillary factor to potentiate and amplify the chronic inflammatory aggression to myocardial tissue.
|
Myocardial Damage Directly Related to Parasite Persistence |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Chagas cardiomyopathy is essentially a myocarditis, and the inflammatory process, although more conspicuous in the acute phase, is clinically silent but incessant in patients with the indeterminate and chronic phases of the disease, as shown by studies in experimental models82 and in necropsy (chagasic patients dead from other causes) and biopsy specimens.83–85 The prevalence of myocarditis correlates with the severity of clinical heart failure86 and a significant correlation between ventricular dilation, inflammatory changes, and fibrosis was found in a Syrian hamster model of Chagas cardiomyopathy.87 Moreover, clinical progression and survival were significantly worse in patients with Chagas heart disease as compared with patients with noninflammatory forms of dilated cardiomyopathy.88 In addition, although the molecular mechanisms that determine how the host–parasite interaction is regulated in regard to invasion location and parasite tissue retention, it has been suggested that variations in tissue tropism, dependent on genetic properties of parasite and host, could explain the different clinical forms of Chagas disease.89
Since the initial pathological studies, the tissue damage in the heart and gastroenteric tract, which occurred in the acute phase, has been clearly related to the intense parasitemia and parasitism of target organs.51 Histopathological studies in the chronic phase of the disease, however, showed very low-grade myocardial fiber parasitism and an intriguing lack of topographical correlation between inflammatory foci and amastigote T cruzi nests.5,90 On the basis of this evidence, the role of the parasite in the genesis of cardiac damage during the chronic phase of Chagas disease has been questioned by proponents of alternative pathogenetic hypotheses.9,91 However, the evidence of typical chronic focal diffuse lymphocytic myocarditis, with myocytolytic necrosis that occur in areas where no parasite elements could be seen, was largely based on studies that used traditional histological techniques now considered highly insensitive to identify parasites in the infected host.92 Thus, first in animal models of chagasic myocarditis93,94 and later in humans,95–98 several independent investigators employed immunohistochemistry, polymerase chain reaction, and in situ hybridization methods to identify tissue T cruzi antigens or its genomic material in the inflammatory foci. These studies have completely reversed that concept and renewed the focus on a pathogenetic role for myocardial aggression directly dependent on parasite persistence in host tissues (Figure 6). Although a clear-cut correlation between the tissue parasite burden and the intensity of the inflammatory process has been described in experimental animals,99 these findings were not replicated in heart samples from patients.100,101 It is relevant that infected mice, in spite of the development of chronic myocarditis, do not evolve to heart failure and death as occurs in human Chagas disease.
|
That the persistence of T cruzi is directly implicated in the pathology of the chronic phase is also suggested by experimental models of Chagas disease that show parasite load reduction by trypanocidal treatment and concomitant attenuation of cardiomyopathy.102,103 Conversely, in these models, enhancement of parasite burden results in exacerbation of the cardiomyopathy course.104–106 Moreover, during the chronic phase the intact amastigote parasites may coexist within the host tissue,98 even after trypanocidal treatment,107,108 and they may undergo active multiplication during favorable conditions (see below).
Also supportive of the concept of tissue parasitism in the pathogenesis of chronic Chagas disease is the persuasive evidence of organ specificity of the parasite infection that translates into clinical expression of disease. Thus, T cruzi genetic material was not detectable in the heart from seropositive autopsied patients who had died without signs of cardiac involvement, but this material is consistently found in heart specimens from patients with chronic Chagas cardiomyopathy.96 Subsequent studies showed the same proportion of T cruzi DNA among patients with Chagas cardiomyopathy and the indeterminate form of disease.98,100 In addition, T cruzi DNA was detected in esophageal tissue from patients with clinical involvement of this organ, but not from patients dying of isolated cardiac disease.109 Finally, there is evidence that T cruzi strain, its load during the acute phase of infection, parasitemia levels assessed by polymerase chain reaction, and reinfection could influence the chronic phase course.110–114
The exact mechanism whereby parasitism causes tissue damage in the chronic phase is unclear. Although direct myocyte aggression by the parasite is as yet an unproven possibility, and apoptosis may be seen in advanced stages of heart failure,115 the stimulation of immune responses that are targeted at the parasite and self tissues is the most likely cause of inflammation and myocytolysis.
|
Immunologic Mechanisms |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Several independent investigations have shown that diffuse myocarditis with myocytolysis and reparative fibrosis, the hallmark of chronic Chagas heart disease, has the characteristics of a delayed hypersensitivity reaction, with the inflammatory infiltrates composed mainly of mononuclear cells.52,116–119 Together with the demonstration of immunoglobulin and complement deposition in myocardial tissue, these findings constitute first-line evidence for the involvement of immunologic factors in the pathogenesis of Chagas cardiomyopathy.120
Parasite Antigen-Driven Immunopathology and Autoimmunity in Cardiac Inflammatory Lesions
Despite clear evidence for the participation of immune responses in myocardial damage, the nature of the essential antigen or antigens that elicit destructive immune responses remains elusive. As discussed above, T cruzi antigen and DNA have been identified in cardiac tissue from chronic Chagas disease patients, and T cruzi–specific CD8+ T cells were isolated in endomyocardial biopsy material from patients with Chagas heart disease.121 This provides evidence for the recruitment and expansion of T cruzi–specific T cells to the myocardium, possibly related to parasite persistence in the chronic phase of Chagas heart disease. The T cruzi materials found in the myocardium of chronic chagasic patients are definitely scarce, however, in comparison with the intensity of the myocarditis. Moreover, the parasite that infests the myocardium in the acute phase of disease does not immediately lead to the lesions that later are typically found in the chronic phase. This constitutes the prominent time-scale dissociation between the acute infection and the characteristic morbidity that occurs in the late stage. Furthermore, T cruzi DNA—but not intact T cruzi—has been detected in cardiac tissue from patients with both the indeterminate and overt cardiomyopathic forms.120 Finally, sometimes the foci of amastigote-parasitized myocardial cells remain free of inflammation despite intense parasitism of myocardial tissue. Together, these findings indicate that the topographical and temporal relation between the parasite presence and the development of myocardial pathology is far from straightforward. Similarly, the intensity of parasitemia is not directly related to the clinical evolution of patients in the chronic phase of Chagas disease. Thus, some other factor must operate along with parasite persistence to lead a subgroup of T cruzi–infected individuals to progressive and incessant myocardial damage. Early investigators reported that inoculation of T cruzi homogenates induced inflammatory lesions in the myocardium of rhesus monkeys, which established the autoimmunity/antigenic mimicry hypothesis of pathogenesis.116 It was then hypothesized that the breakdown of immunologic tolerance and consequent cardiac damage could be secondary to an originally protective response directed to a given T cruzi antigen that bore structural similarities to specific myocardial components. Several mechanisms have been postulated to trigger autoimmunity after T cruzi infection120: antigen exposure secondary to tissue damage, followed by sensitization in the inflammatory environment (ie, bystander activation); molecular mimicry, whereby T and B cells recognize parasite antigens that share structurally similar epitopes with host antigens, which generates cross-reactive autoimmune responses (Table 2); and polyclonal activation that leads to autoantibody production. Autoimmune and T cruzi–specific responses secondary to parasite persistence are not incompatible or mutually exclusive in Chagas disease, and a combination of these types of immune responses may be involved in the establishment of myocardial damage.
|
Humoral Immune Phenomena in Acute and Chronic Human Chagas Disease
Shortly after the acute infection starts, the high-grade tissue parasitism elicits a strong cellular and humoral immune response against T cruzi, which leads to biological control but not elimination of the parasite. Macrophages and dendritic cells promote endocytosis of the parasites, and with the ensuing expression of interleukin (IL)-12 and costimulatory molecules they prime interferon 
(IFN-)–producing T cruzi–specific T cells that migrate in response to chemokines that are locally released and participate in the immune response against the parasite.122
In chronic human T cruzi infection, the cytokine profile remains shifted toward Th1 cytokines such as IFN- with suppression of Th2 cytokines such as IL-4123,124 and elevated plasma levels of tumor necrosis factor-
.125 In addition, CD4+ peripheral blood mononuclear cells from chronic Chagas cardiomyopathy patients produce more IFN- and less IL-10 than chagasic patients in the asymptomatic/indeterminate phase,124,126 which thus supports the notion that patients who evolve to chronic Chagas cardiomyopathy develop an exacerbated Th1 immune response. Plasma tumor necrosis factor- levels are further increased in patients with more severe cardiac involvement.120,125 Moreover, chagasic patients with more severe cardiomyopathy who carry tumor necrosis factor- alleles associated with high cytokine production have significantly shorter survival as compared with carriers of other alleles.127 Polymorphisms in several inflammatory genes (lymphotoxin-, BAT1, membrane cofactor protein-1) have also been implicated in the development of Chagas cardiomyopathy.128,129 In addition, immunogenetic differences probably determine differential susceptibility to factors that lead to the development of Chagas heart disease by modulation of the intensity of both protective and tissue-damaging immune responses.
The inflammatory infiltrate in Chagas heart disease includes macrophages, CD8+ T cells that express granzyme, and CD4+ T cells.120 There is also evidence for augmented local expression of adhesion molecules; human leukocyte antigen class I and IIL molecules; the chemokines membrane cofactor protein-1, IL-10, and measles immunoglobulin; the CCR2 and CXCR3 chemokine receptors; and the cytokines IFN-, tumor necrosis factor-, IL-6, and IL-4130. Significant signaling by IFN- has also been observed in the myocardium of patients with Chagas cardiomyopathy, and IFN- and membrane cofactor protein-1 increased expression of atrial natriuretic factor, which is a marker of cardiomyocyte hypertrophy and heart failure in neonatal murine cardiomyocytes.130 Taken together, these observations suggest that IFN-–mediated chronic myocardial inflammation could contribute to the pathogenesis of chronic Chagas cardiomyopathy.
Autoimmunity in Experimental Chagas Disease
Experimentally, T cruzi–infected mice display autoantibodies specific for various autoantigens contained in cardiac, nervous, and other tissues (Table 3); structural proteins such as cardiac myosin, desmin, and actin are common targets, and infected mice also develop autoantibodies against the ß1-adrenergic and M2-muscarinic cholinergic receptors.131 Such mice seldom develop end-stage heart failure, however.
|
Cellular autoimmunity directed against heart autoantigens has also been observed in experimental Chagas disease. Passive transfer of CD4+ T cells or T cell lines from chronically T cruzi–infected mice to noninfected syngeneic mice cause myocardial tissue inflammation.132 Also, CD4+ T cells from T cruzi–infected mice recognize cardiac myosin but not actin.133,134 Tolerance induction with a myosin-enriched cardiac homogenate resulted in less myocarditis and fibrosis.135 Given the fact that cardiac myosin is still the single heart-specific–defined T cell autoantigen, these findings support the concept that cardiac myosin is a major autoantigen in chronic murine T cruzi infection. Importantly, immunization with cardiac myosin induces severe T cell–dependent myocarditis in genetically susceptible mice.120 Moreover, T cruzi cross-reactive antigens with both cardiac and noncardiac specificity have been identified, some of them with functional activity (Table 3). Immunization of mice with T cruzi protein cruzipain induced autoantibodies to skeletal and cardiac myosin and against the cardiac muscarinic cholinergic receptor, which led to muscle damage and heart conduction abnormalities.136 Another notable finding was the development of autoreactive anti-heart antibodies and heart functional alterations after the immunization of BALB/c mice with T cruzi ribosomal P1 and P2 protein synthetic peptide.137
Autoimmunity in Human Chagas Cardiomyopathy
Sera from Chagas disease patients contain autoantibodies specific for various autoantigens expressed in cardiac, nervous, and other tissues (Table 3). Sera from >80% of patients contained anti-neuron autoantibodies, and functional antibodies against adrenergic and muscarinic receptors found in sera from arrhythmic chagasic patients induced arrhythmia in explanted rabbit hearts (Tables 2 and 3
). Such functionally active antibodies have also been implicated in the production of autonomic impairment.138
Sera from chronic chagasic patients also contain cross-reactive antibodies between human and T cruzi proteins, many of which are evolutionarily conserved (Table 3). Thus, cross-reactive antibodies between T cruzi and human ribosomal P proteins or the ß1-adrenergic receptor have been detected in chagasic patients.139 Moreover, antibodies cross-reactive between cardiac myosin heavy chain and the T cruzi protein B13 are more frequently found in sera from patients with definite Chagas heart disease than in patients with the indeterminate form of the disease.140 Also, CD4+ T cell clones derived from an endomyocardial biopsy sample from a patient with Chagas cardiomyopathy cross-reactively recognized cardiac myosin and T cruzi protein B13.141 In vitro sensitization of human peripheral lymphocytes with B13 protein peptides elicited cardiac myosin–cross-reactive T cell clones.142,143 The finding of molecular mimicry between cardiac myosin and T cruzi protein B13 indicates that it is antigen receptor crossreactivity, rather than simple antigen exposure bystander activation, that causes antimyosin autoimmunity in human Chagas heart disease.
|
Overview of the Pathogenesis of Chagas Heart Disease |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
Although autonomic derangements and microcirculatory disturbances constitute prominent peculiarities in Chagas cardiomyopathy, their role in the pathogenesis of chronic myocardial lesions is probably ancillary rather than fundamental in the mechanism of disease. Also, similar to what happens in every disease that affects the cardiac shape and dimension, neurohormonal activation per se can lead to a vicious cycle of progressive remodeling in chronic Chagas heart disease.144 Nevertheless, the pathogenesis of chronic Chagas heart disease is inexorably dependent on a low-grade but incessant systemic infection with documented autoimmune reaction. In fact, parasite persistence and immunologic mechanism seem inextricably related in myocardial aggression in the chronic phase of Chagas heart disease (Figure 7). Thus, future research should appropriately focus on the exploration of the logical consequences of both underlying pathogenetic mechanisms and their clinical potential implications and therapeutic opportunities.
|
Determination of whether autoimmunity and molecular mimicry, rather than parasite-driven immunopathology, are causes or consequences of cardiac tissue damage in human and experimental models of Chagas heart disease is key to understanding the essential nature of Chagas cardiomyopathy pathogenesis. Although the recent identification of persistent virus infection in multiple sclerosis and insulin-dependent diabetes mellitus may indicate that infection is a common theme in diseases classically dependent on immunologic mechanism, experimental and clinical data in Chagas heart disease fulfill several of the criteria required for an autoimmune pathogenesis.120 Thus, the identification of heart–T cruzi cell cross-reactive T-cell antigens (Table 3) with reproduction of pathobiological changes by passive transfer of immune cells in murine models, the amelioration of inflammation as a consequence of tolerance induction to myocardial antigens, and the induction of autoimmune disease after immunization with cardiac myosin have all been demonstrated. In addition, the isolation of cardiac myosin-autoreactive T cells in molecular mimicry with T cruzi B13 protein from affected tissue can be considered important indirect evidence. Together with the demonstration that in vitro immunization with B13 protein elicits T cell clones cross-reactive with cardiac myosin, these results suggest a role for autoimmunity targeted to heart autoantigens in the pathogenesis of Chagas heart disease. The finding that immunization with T cruzi ribosomal antigens induced cross-reactive antibodies and heart conduction abnormalities, and that similar cross-reactive autoantibodies present in Chagas heart disease sera induce arrhythmia in explanted hearts, suggest that these disturbances play a pathogenic role in some clinical manifestations of Chagas cardiomyopathy. The transfer of tissue lesions by T cell clones cross-reactive to known host and parasite epitopes, or a successful trial of tolerance to relevant heart-specific antigens among patients, would definitively establish how relevant autoimmunity is as a pathogenic mechanism in Chagas heart disease. A direct feasible test of the relevance of molecular mimicry between a T cruzi antigen and intrinsic heart proteins might be achieved through experimental infection with parasites devoid of the pertinent heart cross-reactive antigen (through genetic manipulation). The failure of this parasite line to induce myosin autoimmunity and/or myocarditis would directly imply molecular mimicry in myosin autoimmunity and Chagas disease pathogenesis. Finally, immunologic intervention (eg, pharmacological cytokine blockade) could be immediately available to millions of patients with Chagas disease in the Americas.
Removal of parasite stimulus has been attempted in experimental models of chronic myocarditis by treatment with trypanocidal drugs after acute infection.112 However, because the effectiveness of trypanocidal treatment is only partial and the currently available assays for parasitological cure are less than ideal, it has been impossible to prove with 100% certainty that the parasite has indeed been removed after treatment. At any rate, the dichotomy between tissue-damaging autoimmunity and systemic parasite persistence may indeed be false in Chagas disease. Even if heart autoantigens were the primary targets for immune responses that produce tissue damage in Chagas heart disease, persistent T cruzi infection supplies a continuous source of cross-reactive antigen presentation and innate immune response stimuli, which triggers and maintains a powerful Th1 cytokine response that may activate and exacerbate the pathogenic potential of T cruzi–specific heart–cross-reactive T and B cell clones.
The notion that the immunologic system acts to control parasitism at low levels is supported by the evidence that reactivation of infection consistently occurs under immunosuppression treatment to prevent transplant rejection or in patients with virally acquired immunodeficiency syndromes.145,146 Recent cross-sectional studies in chronic chagasic patients that correlate severity of heart disease to the maturation and migratory properties of the memory CD8+ T cell compartment are consistent with the hypothesis of a gradual clonal exhaustion in the CD8+ T cell population, most likely as a result of continuous antigenic stimulation by persistent parasites.147 There is also emerging experimental evidence that genetic immunization (ie, injection of DNA that encodes T cruzi antigen genes that can be expressed in the host) can elicit antigen-specific protective immune responses, which decreases disease severity in the murine model of Chagas disease.148
These findings also suggest that effective vaccine-mediated control of T cruzi infection may prevent the clinical development of Chagas disease. Another clinical implication is that effective measures to control the parasite burden should be welcome and probably would reduce tissue damage. In fact, trypanocidal therapy has been shown to improve parasite–host related outcomes (eg, benznidazole significantly reduced the proportion of positive xenodiagnosis in both children and adults and increased the rate of negative seroconversion in asymptomatic chagasic patients149). Systematic reviews of published controlled trials on both asymptomatic individuals and patients with overt Chagas cardiomyopathy, however, showed that there are insufficient data to provide evidence that currently available trypanocidal therapy can alter clinical outcomes in chronic Chagas disease.149,150 The BENEFIT Trial (Benznidazole Evaluation for Interrupting Trypanosomiasis): Evaluation of the Use of an Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas Heart Disease, a large, randomized, double-blind, controlled study of benznidazole versus placebo in patients with chronic Chagas heart disease, is currently being performed to overcome this therapeutic dilemma.
|
Acknowledgments |
|---|
Disclosures
Drs Marin-Neto, Maciel, and Simões have received research grants from FAPESP–Foundation for Research of State of São Paulo. Drs Cunha-Neto, Maciel, and Simões have received research grants from Conselho Nacional de Pesquisa–CNPq–Millenium Institute.
|
References |
|---|
|
TopAbstractIntroductionDysautonomiaMicrovascular DisturbancesMyocardial Damage Directly...Immunologic MechanismsOverview of the Pathogenesis...References |
|---|
1. Chagas C. Über eine neue Trypanosomiasis des Menschen. 1909;Band XIII:5–7. Located at: Archiv für Schiffs–und Tropen–Hygiene.
2. Prata A. Clinical and epidemiological aspects of Chagas’ disease. Lancet Infect Dis. 2001; 1: 92–100.[CrossRef][Medline] [Order article via Infotrieve]
3. Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas’ disesase? Trends in Parasitology. 2005; 21: 513–516.[CrossRef][Medline] [Order article via Infotrieve]
4. Dias JCP. The indeterminate form of human chronic Chagas’ disease: a clinical epidemiological review. Rev Soc Bras Med Trop. 1989; 22: 147–156.[Medline] [Order article via Infotrieve]
5. Laranja FS, Dias E, Nobrega G, Miranda A. Chagas’ disease: a clinical, epidemiologic and pathologic study. Circulation. 1956; 14: 1035–1059.[Medline] [Order article via Infotrieve]
6. Chagas C, Vilella E. Cardiac form of American trypanosomiasis. Mem Inst Oswaldo Cruz. 1922; 14: 5–61.
7. Oria J, Ramos J. Alterações do metassimpático do coração nos portadores de megaesôfago. Arq Bras Cardiol. 1949; 2: 311–316.
8. Köberle F. Cardiopathia parasympaticopriva. München Med Wschr. 1959; 101: 1308–1310.[Medline] [Order article via Infotrieve]
9. Köberle F. Chagas’ heart disease and Chagas’ syndromes: the pathology of American trypanosomiasis. Adv Parasitol. 1968; 6: 63–116.[Medline] [Order article via Infotrieve]
10. Mott KE, Hagstrom JWC. The pathologic lesions of the cardiac autonomic nervous system in chronic Chagas’ myocarditis. Circulation. 1965; 31: 273–286.
11. Oliveira JSM. A natural human model of intrinsic heart nervous system denervation: Chagas’ cardiopathy. Am Heart J. 1985; 110: 1092–1098.[CrossRef][Medline] [Order article via Infotrieve]
12. DeSouza MM, Andrade SG, Barbosa Jr AA, Macedo dos Santos RT, Ferreira Alves VA, Andrade ZA. Trypanosoma cruzi strains and autonomic nervous system pathology in experimental Chagas’ disease. Mem Inst Oswaldo Cruz. 1996; 91: 2117–2124.
13. Machado CR, Caliari MV, de Lana M, Tafuri WL. Heart autonomic innervation during the acute phase of experimental American trypanosomiasis in dogs. Am J Trop Med Hyg. 1998; 59: 492–6.[Abstract]
14. Böhm GM. Quantitative study of the intrinsic innervation of the heart endomyocardial fibrosis and African idiopathic cardiopathies. Rev Inst Med Trop SãoPaulo. 1968; 10: 84–88.
15. Amorim DS, Olsen EGJ. Assessment of heart neurons in dilated (congestive) cardiomyopathy. Br Heart J. 1982; 47: 111–118.
16. Lopes ER, Tafuri WL. Involvement of the autonomic nervous system in Chagas’ heart disease. Rev Soc Bras Med Trop. 1983; 16: 206–11.
17. Santos RR, Marquez JO, Furtado CCG, Oliveira JCR, Martins AR, Köberle F. Antibodies against neurons in chronic Chagas’ disease. Tropenmed Parasitol. 1979; 30: 19–23.[Medline] [Order article via Infotrieve]
18. Santos RR, Hudson L. Denervation and the immune response in mice infected with Trypanosoma cruzi. Clin Exp Immunol. 1981; 44: 349–354.[Medline] [Order article via Infotrieve]
19. Amorim DS, Godoy RA, Manço JC, Tanaka A, Gallo Jr L. Effects of acute elevation in blood pressure and of atropine on heart rate in Chagas’ disease: a preliminary report. Circulation. 1968; 38: 289–294.
20. Manço JC, Gallo Jr L, Godoy RA, Fernandes RG, Amorim DS. Degeneration of the cardiac nerves in Chagas’ disease: further studies. Circulation. 1969; 40: 879–885.[Medline] [Order article via Infotrieve]
21. Amorim DS, Mello de Oliveira JA, Manço JC, Gallo Jr L, Meira de Oliveira JS. Chagas’ heart disease: first demonstrable correlation between neuronal degeneration and autonomic impairment. Acta Cardiologica. 1973; 28: 4311–4340.
22. Marin-Neto JA, Gallo Jr L, Manço JC, Rassi A, Amorim DS. Postural reflexes in chronic Chagas’ heart disease: heart rate and arterial pressure responses. Cardiology. 1975; 60: 343–357.[Medline] [Order article via Infotrieve]
23. Gallo Jr L, Marin-Neto JA, Manço JC, Rassi A, Amorim DS. Abnormal heart rate responses during exercise in patients with Chagas’disease. Cardiology. 1975; 60: 147–162.[CrossRef][Medline] [Order article via Infotrieve]
24. Junqueira Jr LF, Gallo Jr L, Manço JC, Marin-Neto JA, Amorim DS. Subtle cardiac autonomic impairment in Chagas’ disease detected by baroreflex sensitivity testing. Braz J Med Biol Res. 1985; 18: 171–178.[Medline] [Order article via Infotrieve]
25. Sousa ACS, Marin-Neto JA, Maciel BC, Gallo Jr L, Amorim DS. Cardiac parasympathetic impairment in gastrointestinal Chagas’ disease. The Lancet. 1987; 8539: 985.
26. Guzzetti S, Iosa D, Pecis M, Bonura M, Prosdocimi M, Malliani A. Impaired heart rate variability in patients with chronic Chagas’ disease. Am Heart J. 1991; 121: 1727–1734.[CrossRef][Medline] [Order article via Infotrieve]
27. Emdin M, Marin-Neto JA, Carpeggiani C, Maciel BC, Macerata A, Pintya AO, Michelassi C, Gallo Jr L, Pola S, Marchesi C, L’Abbate A. Heart rate variability and cardiac denervation in Chagas’ disease. J Amb Monit. 1992; 5: 251–257.
28. Amorim DS, Manço JC, Gallo Jr L, Marin-Neto JA. Chagas’ heart disease as an experimental model for studies of cardiac autonomic function in man. Mayo Clin Proc. 1982; 57: 48–60.[Medline] [Order article via Infotrieve]
29. Amorim DS, Marin-Neto JA. Functional alterations of the autonomic nervous system in Chagas’heart disease. Sao Paulo Med J. 1995; 113: 772–784.[Medline] [Order article via Infotrieve]
30. Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, Simões MV, Maciel BC. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas’ disease. Int J Cardiol. 1998; 65: 261–269.[CrossRef][Medline] [Order article via Infotrieve]
31. Ribeiro ALP, Moraes RS, Ribeiro JP, Ferlin EL, Torres RM, Oliveira E, Rocha MOC. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas’ disease. Am Heart J. 2001; 141: 260–265.[Medline] [Order article via Infotrieve]
32. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1970; 285: 877–883.
33. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, Gauthier DF, Hartley LH. Impaired chronotropic response to exercise in patients with congestive heart failure: role of postsynaptic beta-adrenergic desensitization. Circulation. 1989; 80: 314–23.
34. Marin-Neto JA, Pintya AO, Gallo Jr L, Maciel BC. Abnormal baroreflex control of heart rate in decompensated congestive heart failure and reversal after compensation. Am J Cardiol. 1991; 67: 604–610.[CrossRef][Medline] [Order article via Infotrieve]
35. Köberle F. Enteromegaly and cardiomegaly in Chagas’disease. Gut. 1963; 4: 399–405.[Medline] [Order article via Infotrieve]
36. Adad SJ, Cançado CG, Etchebehere RM, Teixeira VP, Gomes UA, Chapadeiro E, Lopes ER. Neuron count reevaluation in the myenteric plexus of chagasic megacolon after morphometric neurons analysis. Virchows Archives. 2001; 438: 254–258.[CrossRef][Medline] [Order article via Infotrieve]
37. Meneghelli UG. Chagasic enteropathy. Rev Soc Med Trop. 2004; 37: 252–260.
38. Oliveira JSM. Cardiopatia "chagásica" experimental. Rev Goiana Med. 1969; 15: 77–133.
39. Alcântara FG. Denervação dos gânglios cardíacos intramurais e cercicotorácicos na moléstia de Chagas. Rev Goiana Med. 1970; 16: 159–177.
40. Tafuri WL. Pathogenesis of lesions of the autonomic nervous system of the mouse in experimental acute Chagas’ disease. Am J Trop Med Hyg. 1970; 19: 405–417.
41. Camargos ER, Haertel LR, Machado CR. Preganglionic fibers of the adrenal medulla and cervical sympathetic ganglia: differential involvement during experimental American trypanosomiasis in rats. Int J Exp Pathol. 1996; 77: 115–24.[CrossRef][Medline] [Order article via Infotrieve]
42. Oliveira JSM, Soares EG, Muccillo G, Gaspar PR. Non-potentiation of myocardial lesion by isoproterenol in T cruzi-infected rats. Res Exp Med (Berlin). 1984; 184: 33–39.[CrossRef]
43. Miles MA, Cedillos RA, Povoa MM, de Souza AA, Prata A, Macedo V. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas’ disease? Lancet. 1981 Jun 20; 1 (8234): 1338–1340.
44. Dávila DF, Inglessis G, Dávila CAM. Chagas’ heart disease and the autonomic nervous system. Int J Cardiol. 1998; 66: 123–127.[CrossRef][Medline] [Order article via Infotrieve]
45. Simões MV, Pintya AO, Bromberg-Marin G, Sarabanda AVL, Antloga CM, Pazin-Filho A, Maciel BC, Marin-Neto JA. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas’ cardiomyopathy. Am J Cardiol. 2000; 86: 975–81.[CrossRef][Medline] [Order article via Infotrieve]
46. Simões MV, Pintya AO, Sarabanda AV, Pazin-Filho A, Maciel BC, Marin-Neto JA. Reduced [123I]MIBG uptake precedes wall motion impairment in Chagas’ disease. J Nucl Cardiol. 1999; 6: S63.
47. Sterin-Borda E, Sterin Borda L. Andiadrenergic and muscarinic receptor antibodies in Chagas’ cardiomyopathy. Int J Cardiol. 1996; 54: 149–156.[CrossRef][Medline] [Order article via Infotrieve]
48. De Oliveira SF, Pedrosa RC, Nascimento JHM, Carvalho ACC, Masuda MO. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation. 1996; 96: 2031–2037.
49. Baroldi G, Oliveira SJ, Silver MD. Sudden and unexpected death in clinically "silent" Chagas’ disease: a hypothesis. Int J Cardiol. 1997; 58: 263–268.[CrossRef][Medline] [Order article via Infotrieve]
50. Marin-Neto JA, Maciel BC, Gallo Jr L, Junqueira Jr LF, Amorim DS. Effect of parasympathetic impairment on the hemodynamic response to handgrip in Chagas’ heart disease. Br Heart J. 1986; 55: 204–208.
51. Vianna G. Contribuição para o estudo da anatomia patológica da moléstia de Chagas. Mem Inst Oswaldo Cruz. 1911; 3: 276–294.
52. Torres CM. Miocitólise e fibrose do miocárdio na doença de Chagas. Mem Inst Oswaldo Cruz. 1960; 58: 161–182.[Medline] [Order article via Infotrieve]
53. Ferrans VJ, Milei J, Tomiata Y, Storino RA. Basement membrane thickening in cardiac myocytes and capillaries in chronic Chagas’ disease. Am J Cardiol. 1988; 61: 1137–1140.[CrossRef][Medline] [Order article via Infotrieve]
54. Ferreira CS, Lopes ER, Chapadeiro E, Almeida HO, Souza WF, Silva-Neto JJ. Coronariografia post-morten na cardite chagásica crônica: correlação anátomo-radiológica. Arq Bras Cardiol. 1980; 34: 81–86.[Medline] [Order article via Infotrieve]
55. Higuchi ML, Brito T, Parzianello LC, Fukasawa S, Ramires JA. Severe arteriolar dilatation and ischemic lesions in chronic Chagas’ cardiopathy: a 3D confocal laser microscopic study. J Am Coll Cardiol. 1998; 31: 382.
56. Morris AS, Tanowitz HB, Wittner M, Bilezikian JP. Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation. 1990; 82: 1900–1909.
57. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas’ disease. Am Heart J. 1990; 120: 233–236.[CrossRef][Medline] [Order article via Infotrieve]
58. Oliveira JSM, Santos JCM, Muccillo G, Ferreira AL. Increased capacity of the coronary arteries in chronic Chagas’ heart disease: further support for the neurogenic pathogenesis concept. Am Heart J. 1985; 109: 304–308.[CrossRef][Medline] [Order article via Infotrieve]
59. Rossi MA, Gonçalves S, Ribeiro-dos-Santos R. Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice: the potenial role of intravascular platelet aggregation in its genesis. Am J Pathol. 1984; 114: 209–216.[Abstract]
60. Rossi MA, Carobrez SG. Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice: histochemical evidence of hypoxic changes in the myocardium. Br J Exp Pathol. 1985; 66: 155–160.[Medline] [Order article via Infotrieve]
61. Factor SM, Cho S, Wittner M, Tanowitz HB. Abnormalities of the coronary microcirculationin acute murine Chagas’ disease. Am J Trop Med Hyg. 1985; 34: 246–253.
62. Rossi MA. Aortic endothelial cell changes in the acute septicemic phase of experimental Trypanosoma cruzi infection in rats: scanning and transmission electron microscopy study. Am J Trop Med Hyg. 1997; 57: 321–327.
63. Andrade ZA, Andrade SG, Correa R, Sadigursky M, Ferrans VJ. Myocardial changes in acute Trypanosoma cruzi infection: ultrastructural evidence of immune damage and the role of microangiopathy. Am J Path. 1994; 144: 1403–1411.[Abstract]
64. Morris SA, Tanowitz HB, Makman M. Trypanosoma cruzi: alteration of cAMP metabolism following infection of human endothelial cells. Exp Parasit. 1992; 74: 69–76.[CrossRef][Medline] [Order article via Infotrieve]
65. Libby P, Alroy J, Pereira MEA. A neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells. J Clin Invest. 1986; 77: 127–135.[Medline] [Order article via Infotrieve]
66. Tanowitz HB, Burns ER, Sinha KA, Kahn NN, Morris SA, Factor SM, Hatcher VB, Bilezikian JP, Baum SG, Wittner M. Enhanced platelet adherence and aggregation in Chagas’ heart disease: a potential pthogenic mechanism for cardiomyopathy. Am J Trop Med Hyg. 1990; 43: 274–281.
67. Morris SA, Weiss LM, Factor SM, Bilezikian JP, Tanowitz H, Wittner M. Verapamil ameliorates clinical, pathological and biochemical manifestations of the experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol. 1989; 14: 782–789.[Abstract]
68. Tanowitz HB, Kaul DK, Chen B, Morris SA, Factor SM, Weiss LM, Wittner M. Compromised microcirculation in acute murine Trypanosoma cruzi infection. J Parasit. 1996; 82: 124–130.[CrossRef][Medline] [Order article via Infotrieve]
69. Ferreira V, Molina MC, Schwaeble W, Lemus D, Ferreira A. Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis? Trends Parasitol. 2005; 21: 169–174.[CrossRef][Medline] [Order article via Infotrieve]
70. Feit A, El-Sherif N, Korostoff S. Chagas’ disease masquerading as coronary artery disease. Arch Intern Med. 1983; 143: 144–145.
71. Simões MV, Mello-Ayres E, Attab-Santos JL, Schmidt A, Pintya AO, Maciel BC, Marin-Neto JA. Detection of myocardial ischemia in Chagas’ heart disease patients with angina-like symptoms by the effort test and holter monitoring. Arq Bras Cardiol. 1993; 60: 315–319.[Medline] [Order article via Infotrieve]
72. Hammermeister KE, Caeiro T, Crespo E, Palmero H, Gibson DG. Left ventricular wall motion in patients with Chagas’ disease. Br Heart J. 1984; 51: 70–76.
73. Arreaza N, Puigbó JJ, Acquatella H, Casal H, Giordano H, Valecillos R, Mendoza I, Perez JF, Hirschhaut E, Combellas I. Radionuclide evaluation of left ventricular function in chronic Chagas’ cardiomyopathy. J Nucl Med. 1983; 24: 563–567.
74. Hagar JM, Rahintoola SH. Chagas’ heart disease in the United States. N Engl J Med. 1991; 325: 763–768.[Abstract]
75. Torres FW, Acquatella H, Condado JA, Dinsmore R, Palácios IF. Coronary vascular reactivity is abnormal in patients with Chagas’ disease. Am Heart J. 1995; 129: 995–1001.[CrossRef][Medline] [Order article via Infotrieve]
76. Marin-Neto JA, Simões MV, Ayres-Neto EM, Attab-Santos JL, Gallo Jr L, Amorim DS, Maciel BC. Studies of the coronary circulation in Chagas’ heart disease. São Paulo Med J. 1995; 113: 826–834.[Medline] [Order article via Infotrieve]
77. Castro R, Kuschnir E, Sgammini H. Evaluacion de la performance cardíaca y perfusion miocárdica com radiotrazadores em la cardiopatia chagásica crônica. Fed Arg Cardiol. 1988; 17: 226–231.
78. Marin-Neto JA, Marzullo P, Marcassa C, Gallo Jr L, Maciel BC, Bellina CR, L’Abbate AL. Myocardial perfusion abnormalities in chronic Chagas’ disease as detected by thallium-201 scintigraphy. Am J Cardiol. 1992; 69: 780–784.[CrossRef][Medline] [Order article via Infotrieve]
79. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R. Miocardipatia chagásica crônica: effectos del dipiridamol sobre la dinâmica ventricular. Arq Bras Cardiol. 1983; 41: 373–378.[Medline] [Order article via Infotrieve]
80. Marin-Neto JA, Souza ACS, Maciel BC, Gallo Jr L, Iazigi N. Avaliação angiocardiográfica nuclear do efeito do dinitrato de isosorbitol em pacientes chagásicos. Arq Bras Cardiol. 1988; 51: 367–371.[Medline] [Order article via Infotrieve]
81. Pasternac A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982; 65: 778–788.
82. Andrade ZA, Andrade SG, Sadigursky M, Wenthold Jr RJ, Hilbert SL, Ferrans VJ. The indeterminate phase of Chagas’ disease: ultrastructural characterizaton of cardiac changes in the canine model. Am J Trop Med Hyg. 1997; 57: 328–336.
83. Lopes ER, Chapadeiro E, Almeida HO, Rocha A. Contribuição ao estudo da anatomia patológica dos corações de chagásicos falecidos subitamente. Rev Soc Bras Med Trop. 1975; 9: 269–282.
84. Barreto ACP, Mady C, Arteaga-Fernandez E, Stolf N, Lopes EA, Higuchi ML, Bellotti G, Pileggi F. Right ventricular endomyocardial biopsy in chronic Chagas’ disease. Am Heart J. 1986; 111: 307–318.[CrossRef][Medline] [Order article via Infotrieve]
85. Carrasco Guerra HA, Palacios-Pru E, Dagert de Scorza C, Molina C, Inglessis G, Mendoza RV. Clinical histochemical and ultrastructural correlation in septal endomyocardial biopsies from chronic chagasic patients. Am Heart J. 1987; 113: 716–724.[CrossRef][Medline] [Order article via Infotrieve]
86. Higuchi ML, De Morais CF, Pereira Barreto AC, Lopes EA, Stolf N, Bellotti G, Pileggi F. The role of active myocarditis in the development of heart failure in chronic Chagas’ disease: a study based on endomyocardial biopsies. Clin Cardiol. 1987; 10: 665–670.[Medline] [Order article via Infotrieve]
87. Bilate AM, Salemi VM, Ramires FJ, de Brito T, Silva AM, Umezawa ES, Mady C, Kalil J, Cunha-Neto E. The Syrian hamster as a model for the dilated cardiomyopathy of Chagas’ disease: a quantitative echocardiographical and histopathological analysis. Microbes Infect. 2003; 5: 1116–1124.[CrossRef][Medline] [Order article via Infotrieve]
88. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int J Cardiol. 2005; 102: 239–247.[CrossRef][Medline] [Order article via Infotrieve]
89. Andrade LO, Andrews NW. The Trypanosoma cruzi-host-cell interplay: location, invasion, retention. Nat Rev Microbiol. 2005; 3: 819–823.[CrossRef][Medline] [Order article via Infotrieve]
90. Andrade ZA, Andrade SG. The pathology of Chagas’ disease (cardiac chronic form). Bol Fund G Moniz. 1955; 6: 1–53.
91. Kalil J, Cunha-Neto E. Autoimmunity in Chagas disease cardiomyopathy: fulfilling the criteria at last? Parasitol Today. 1996; 12: 396–399.[CrossRef][Medline] [Order article via Infotrieve]
92. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001; 31: 550–554.[Medline] [Order article via Infotrieve]
93. Ben Younes-Chennoufi A, Hontebeyrie-Joskowicz M, Tricottet V, Eisen H, Reynes M, Said G. Persistence of Trypanosoma cruzi antigens in the inflammatory lesions of chronically infected mice. Trans R Soc Trop Med Hyg. 1988; 82: 77–83.[CrossRef][Medline] [Order article via Infotrieve]
94. Franco MF. Experimental carditis induced by Trypanosoma cruzi (y strain) in guinea pigs: correlation between histopathology and the presence of T cruzi antigens identified by indirect immunofluorescence. Rev Soc Bras Med Trop. 1990; 23: 187–189.
95. Higuchi ML, Brito T, Reis MM, Barbosa A, Bellotti G, Pereira-Barreto AC, Pileggi F. Correlation between T cruzi parasitism and myocardial inflammation in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol. 1993; 2: 101–106.
96. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am Trop Med Hyg. 1993; 48: 348–357.
97. Bellotti G, Bocchi E, de Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, Esteves-Filho A, Kalil R, Weiss R, Jatene A, Pileggi F. In vivo detection of T cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J. 1996; 131: 301–307.[CrossRef][Medline] [Order article via Infotrieve]
98. Añez N, Carrasco H, Parada H, Crisante G, Rojas A. Fuenmayor C, Gonzalez N, Percoco G, Borges R, Guevara P, Ramirez JL. Myocardial parasite persistence in chronic Chagasic patients. Am J Trop Med Hyg. 1999; 60: 726–732.[Abstract]
99. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas disease. J Infect Dis. 1999; 80: 480–486.
100. Olivares-Villagomez D, McCurley TL, Vnencak-Jones CL, Correa-Oliveira R, Colley DG, Carter CE. Polymerase chain reaction amplification of three different Trypanosoma cruzi DNA sequences from human chagasic cardiac tissue. Am J Trop Med Hyg. 1998; 59: 563–570.[Abstract]
101. Palomino SA, Aiello VD, Higuchi ML. Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens. Ann Trop Med Parasitol. 2000; 94: 571–579.[Medline] [Order article via Infotrieve]
102. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz. 1991; 86: 187–200.[Medline] [Order article via Infotrieve]
103. Garcia S, Ramos CO, Senra JFV, Vilas-Boas F, Rodrigues MM, Carvalho ACC, Ribeiro-dos-Santos R, Soares MBP. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005; 49: 1521–1528.
104. Andrade ZA, Andrade SG, Sadigursky M. Enhancement of chronic Trypanosoma cruzi myocarditis in dogs treated with low doses of cyclophosphamide. Am J Pathol. 1987; 127: 467–473.[Abstract]
105. Silva JS, Rossi MA. Intensification of acute Trypanosoma cruzi myocarditis in BALB/c mice pretreated with low doses of cyclophosphamide or gamma irradiation. J Exp Pathol. 1990; 71: 33–39.
106. Okumura M, Mester M, Iriya K, Amato Neto V, Gama-Rodrigues J. Effects of immunosuppression and benznidazole on Trypanosoma cruzi parasitism during experimental acute Chagas’ disease. Transplant Proc. 1994; 26: 1587–1589.[Medline] [Order article via Infotrieve]
107. Fragata-Filho AA, Luquetti AO, Prata A, Rassi A, Gontijo ED, Ferreira HO, Cançado JR, Coura JR, Andrade SG, Macedo V, Amato-Neto V, Oliveira Jr W, Brener Z. Etiological treatment for Chagas’ disease. Parasit Today. 1997; 13: 127–128.[CrossRef]
108. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira ARL. Persistent infections in chronic Chagas’ disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop S Paulo. 2000; 42: 157–161.[Medline] [Order article via Infotrieve]
109. Vago AR, Macedo AM, Adad SJ, Reis DD, Correa-Oliveira R. PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas disease. Lancet. 1996; 348: 891–892.[CrossRef][Medline] [Order article via Infotrieve]
110. Pereira JB, Wilcox HP, Coura JR. The evolution of chronic chagasic cardiopathy: I: the influence of parasitemia. Rev Soc Bras Med Trop. 1992; 25: 101–108.[Medline] [Order article via Infotrieve]
111. Montamat EE, De Luca D’oro GM, Galerano RH, Sosa R, Blanco A. Characterization of Trypanosoma cruzi population by zymodemes: correlation with clinical picture. Am J Trop Med Hyg. 1996; 55: 625–628.
112. Marinho CRF, Lima MRD, Grisotto MG, Alvarez JM. Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas’ disease. Infect Immun. 1999; 67: 308–318.
113. Bustamante JM, Rivarola HW, Fernandez AR, Enders JE, Fretes R, Palma JA, Paglini-Oliva PA. Indeterminate Chagas’ disease: Trypanosoma cruzi strain and re-infection are factors involved in the progression of cardiopathy. Clin Science. 2003; 104: 415–420.[CrossRef][Medline] [Order article via Infotrieve]
114. Basquiera AL, Sembaj A, Aguerri AM, Omelianiuk M, Guzmán S, Moreno Barral J, Caeiro TF, Madoery RJ, Salomone OA. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. Heart. 2003; 89: 1186–1190.
115. Tostes Jr S, Rocha-Rodrigues DB, Pereira GA, Rodrigues Jr V. Myocardiocyte apoptosis in heart failure in chronic Chagas’ disease. Int J Cardiol. 2005; 99: 233–237.[CrossRef][Medline] [Order article via Infotrieve]
116. Torres CM. Sobre a anatomia patológica da doença de Chagas. Mem Inst Oswaldo Cruz. 1941; 36: 391–404.
117. Muniz J, Azevedo AP. Novo conceito da patogenia da "doença de Chagas" "Tripanosomiasis americana": inflamação alérgica granulomatóide (A), e miocardite hiperérgica (B) produzidas em "rhesus" "Macacca mulatta" inoculados com formas mortas de cultivo do "Schizotrypanum cruzi" (Nota prévia). O Hospital. 1947; 32: 165–183.
118. Andrade ZA. Mechanisms of myocardial damage in Trypanosoma cruzi infection. Ciba Found Symp. 1983; 99: 214–233.[Medline] [Order article via Infotrieve]
119. Higuchi MD, Gutierrez PS, Aiello VD, Palomino S, Bocchi E, Kalil J, Bellotti G, Pileggi F. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Patho Anat Histopathol. 1993; 423: 157–160.[CrossRef]
120. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity. 2006; 39: 41–54.[CrossRef][Medline] [Order article via Infotrieve]
121. Fonseca SG, Moins-Teisserenc H, Clave E. Ianni B, Nunes Vl, Mady C, Iwai LK, Sette A, Sidney J, Marin ML, Goldberg AC, Guilherme L, Charron D, Toubert A, Kalil J, Cunha-Neto E. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8(+) epitopes recognized by T cells from chronically Trypanosoma cruzi–infected patients Microbes Infect. 2005; 7: 688–697.[Medline] [Order article via Infotrieve]
122. Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol. 2002; 18: 262–265.[CrossRef][Medline] [Order article via Infotrieve]
123. Ribeirao M, Pereira-Chioccola VL, Renia L, Augusto Fragata FA, Schenkman S, Rodrigues MM. Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase. Parasite Immunol. 2000; 22: 49–53.[CrossRef][Medline] [Order article via Infotrieve]
124. Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, Bocchi EA, Teixeira HC, Mady C, Kalil J, Cunha-Neto E. Chronic Chagas’ disease cardiomyopathy patients display an increased IFN- response to Trypanosoma cruzi infection. J Autoimmun. 2001; 17: 99–107.[CrossRef][Medline]
[Order article via Infotrieve]
125. Ferreira R, Ianni B, Abel LCJ, Buck P, Mady C, Kalil J, Cunha-Neto E. Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz. 2003; 98: 407–411.[Medline] [Order article via Infotrieve]
126. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect Immun. 2003; 71: 1185–1193.
127. Drigo SA, Cunha-Neto E, Ianni B, Cardoso MR, Braga PE, Fae KC, Nunes VL, Buck P, Mady C, Kalil J, Goldberg AC. TNF gene polymorphisms are associated with reduced survival in severe Chagas disease cardiomyopathy patients. Microbes Infect. In press.
128. Ramasawmy R, Cunha-Neto E, Faé KC, Müller NG, Cavalcanti VL, Drigo SA, Ianni B, Mady C, Kalil J, Goldberg AC. HLA-B associated transcript 1, a putative anti-inflammatory gene, is associated with chronic Chagas’ cardiomyopathy. J Infectious Dis. In press.
129. Ramasawmy R, Cunha-Neto E, Faé KC, Martello FG, Müller NG, Cavalcanti VL, Ianni B, Mady C, Kalil J, Goldberg AC. The monocyte chemoattractant protein-1 (CCL2/MCP-1) gene polymorphism is associated with cardiomyopathy in human Chagas’ disease. Clin Infectious Dis. In press.
130. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, Higuchi ML, Koyama NS, Silva JS, Kalil J, Liew CC. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas’ disease cardiomyopathy. Am J Pathol. 2005; 167: 305–313.
131. Cunha-Neto E, Iwai LK, Bilate AMB, Fonseca SG, Kalil J. Autoimmunity in Chagas’ Disease. In: Shoenfeld Y, Rose NR, eds., Infection and Autoimmunity. Amsterdam, The Netherlands, Elsevier, 2004: 449–472.
132. Ribeiro-Dos-Santos R, Mengel JO, Postol E, Soares RA, Ferreira-Fernandez E, Soares MB, Pontes-De-Carvalho LC. A heart-specific CD4+ T-cell line obtained from a chronic chagasic mouse induces carditis in heart-immunized mice and rejection of normal heart transplants in the absence of Trypanosoma cruzi. Parasite Immunol. 2001; 23: 93–101.[CrossRef][Medline] [Order article via Infotrieve]
133. Rizzo LV, Cunha-Neto E, Teixeira AR. Autoimmunity in Chagas’ disease: specific inhibition of reactivity of CD4+ T cells against myosin in mice chronically infected with Trypanosoma cruzi. Infect Immun. 1989; 57: 2640–2644.
134. Leon JS, Godsel LM, Wang K, Engman DM. Cardiac myosin autoimmunity in acute Chagas heart disease. Infect Immun. 2001; 69: 5643–5649.
135. Pontes de Carvalho L, Santana CC, Soares MB, Oliveira GG, Cunha-Neto E, Ribeiro Dos Santos R. Experimental chronic Chagas’ disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun. 2002; 18: 131–138.[CrossRef][Medline] [Order article via Infotrieve]
136. Giordanengo L, Fretes R, Diaz H, Cano R, Bacile A, Vottero-Cima E, Gea S. Cruzipain induces autoimmune response against skeletal muscle and tissue damage in mice. Muscle Nerve. 2000; 23: 1407–1413.[CrossRef][Medline] [Order article via Infotrieve]
137. Motran CC, Fretes RE, Cerban FM, Rivarola HW, Vottero de Cima E. Immunization with the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins induces long-term duration cross-reactive antibodies with heart functional and structural alterations in young and aged mice. Clin Immunol. 2000; 97: 89–94.[CrossRef][Medline] [Order article via Infotrieve]
138. Goin JC, Leiros CP, Borda E, Sterin-Borda L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J. 1997; 11: 77–83.[Abstract]
139. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebesgue D, Chiale P, Elizari M, Rosenbaum M, Hoebeke J. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med. 1995; 182: 59–65.
140. Cunha-Neto E, Duranti M, Gruber A, Zingales B, De M, I, Stolf N, Bellotti G, Patarroyo ME, Pilleggi F, Kalil J. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci U S A. 1995; 92: 3541–3545.
141. Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. J Clin Invest. 1996; 98: 1709–1712.[Medline] [Order article via Infotrieve]
142. Abel LC, Kalil J, Cunha NE. Molecular mimicry between cardiac myosin and Trypanosoma cruzi antigen B13: identification of a B13-driven human T cell clone that recognizes cardiac myosin. Braz J Med Biol Res. 1997; 30: 1305–1308.[Medline] [Order article via Infotrieve]
143. Iwai LK, Juliano MA, Juliano L, Kalil J, Cunha-Neto E. T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain. J Autoimmun. 2005; 24: 111–117.[CrossRef][Medline] [Order article via Infotrieve]
144. Davila DF, Rossell O, Bellabarba GA. Pathogenesis of chronic Chagas’ heart disease: parasite persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation. Int J Parasitol. 2002; 32: 107–109.[CrossRef][Medline] [Order article via Infotrieve]
145. Bocchi EA, Fiorelli A; First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology. The Brazilian experience with heart transplantation:a multicenter report. J Heart Lung Transplant. 2001; 20: 637–45.[CrossRef][Medline] [Order article via Infotrieve]
146. Harms G, Feldmeier H. The impact of HIV infection on tropical diseases. Infect Dis Clin North Am. 2005; 19: 121–135.[CrossRef][Medline] [Order article via Infotrieve]
147. Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, Tarleton RL, Postan M. Trypanosoma cruzi modulates the profile of memory CD81 T cells in chronic Chagas’ disease patients. Int Immunol. 2006; 18: 465–471.
148. Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun. 2002; 70: 5547–5555.
149. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2002; 1: CD003463.[Medline] [Order article via Infotrieve]
150. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. 2005; 4: CD004102.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  V. Schmitz, E. Svensjo, R. R. Serra, M. M. Teixeira, and J. Scharfstein Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors J. Leukoc. Biol., June 1, 2009; 85(6): 1005 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hiss, T. F. Lascala, B. C. Maciel, J. A. Marin-Neto, and M. V. Simoes Changes in myocardial perfusion correlate with deterioration of left ventricular systolic function in chronic Chagas' cardiomyopathy. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 164 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Schwartz and O. Wexler Early identification and monitoring progression of Chagas' cardiomyopathy with SPECT myocardial perfusion imaging. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 173 - 175. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Lamon and D. P. Hajjar Inflammation at the Molecular Interface of Atherogenesis: An Anthropological Journey Am. J. Pathol., November 1, 2008; 173(5): 1253 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. da Silva, M. M. Batista, D. d. G. J. Batista, E. M. de Souza, P. B. da Silva, G. M. de Oliveira, A. S. Meuser, A.-R. Shareef, D. W. Boykin, and M. d. N. C. Soeiro In Vitro and In Vivo Studies of the Trypanocidal Activity of a Diarylthiophene Diamidine against Trypanosoma cruzi Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3307 - 3314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yacoub, A. O. Mocumbi, and M. H Yacoub Neglected tropical cardiomyopathies: I. Chagas disease Heart, February 1, 2008; 94(2): 244 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bern, S. P. Montgomery, B. L. Herwaldt, A. Rassi Jr, J. A. Marin-Neto, R. O. Dantas, J. H. Maguire, H. Acquatella, C. Morillo, L. V. Kirchhoff, et al. Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review JAMA, November 14, 2007; 298(18): 2171 - 2181. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||